Callahan Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.8M Sell
562,533
-65,185
-10% -$1.74M 1.32% 27
2025
Q4
$15.6M Sell
627,718
-86,079
-12% -$2.17M 1.28% 26
2025
Q3
$18.2M Buy
713,797
+43,454
+6% +$1.07M 1.54% 17
2025
Q2
$16.2M Buy
670,343
+94,846
+16% +$2.21M 1.46% 20
2025
Q1
$14.6M Buy
575,497
+87,203
+18% +$2.28M 1.39% 24
2024
Q4
$13M Buy
488,294
+69,155
+16% +$1.88M 1.22% 28
2024
Q3
$12.1M Buy
419,139
+33,762
+9% +$985K 1.18% 29
2024
Q2
$10.8M Buy
385,377
+94,140
+32% +$2.59M 1.12% 29
2024
Q1
$8.08M Buy
291,237
+76,429
+36% +$2.12M 0.85% 42
2023
Q4
$6.18M Sell
214,808
-86,499
-29% -$2.61M 0.72% 48
2023
Q3
$9.99M Sell
301,307
-19,941
-6% -$705K 1.26% 29
2023
Q2
$11.8M Buy
321,248
+2,662
+0.8% +$104K 1.43% 26
2023
Q1
$13M Sell
318,586
-23,970
-7% -$1.04M 1.68% 22
2022
Q4
$17.6M Sell
342,556
-15,799
-4% -$757K 2.4% 10
2022
Q3
$15.7M Sell
358,355
-8,990
-2% -$437K 2.25% 9
2022
Q2
$19.3M Sell
367,345
-15,534
-4% -$792K 2.56% 6
2022
Q1
$19.8M Sell
382,879
-12,923
-3% -$671K 2.26% 7
2021
Q4
$23.4M Buy
395,802
+37,059
+10% +$1.84M 2.62% 6
2021
Q3
$15.4M Buy
358,743
+14,706
+4% +$651K 1.94% 11
2021
Q2
$13.5M Buy
344,037
+4,819
+1% +$187K 1.71% 17
2021
Q1
$12.3M Buy
339,218
+6,460
+2% +$229K 1.66% 21
2020
Q4
$12.2M Sell
332,758
-23,892
-7% -$876K 1.79% 20
2020
Q3
$12.4M Buy
356,650
+1,723
+0.5% +$60.4K 2.03% 17
2020
Q2
$11M Buy
354,927
+13,141
+4% +$446K 1.95% 17
2020
Q1
$10.6M Buy
341,786
+5,441
+2% +$185K 2.22% 16
2019
Q4
$12.5M Buy
336,345
+5,941
+2% +$212K 2% 17
2019
Q3
$11.3M Buy
330,404
+11,527
+4% +$419K 1.97% 18
2019
Q2
$13.1M Sell
318,877
-544
-0.2% -$21.6K 2.35% 10
2019
Q1
$12.9M Buy
319,421
+6,799
+2% +$272K 2.4% 7
2018
Q4
$12.9M Sell
312,622
-3,392
-1% -$141K 2.76% 6
2018
Q3
$13.2M Buy
316,014
+2,617
+0.8% +$101K 2.45% 7
2018
Q2
$10.8M Buy
313,397
+4,343
+1% +$148K 2.13% 12
2018
Q1
$10.4M Buy
309,054
+1,584
+0.5% +$54.5K 2.13% 11
2017
Q4
$10.6M Buy
307,470
+2,046
+0.7% +$69.8K 2.1% 14
2017
Q3
$10.3M Buy
305,424
+7,631
+3% +$245K 2.18% 11
2017
Q2
$9.49M Buy
297,793
+3,375
+1% +$106K 2.07% 13
2017
Q1
$9.56M Buy
294,418
+5,455
+2% +$172K 2.15% 14
2016
Q4
$8.9M Buy
288,963
+12,548
+5% +$383K 2.15% 13
2016
Q3
$8.88M Buy
276,415
+16,173
+6% +$541K 2.22% 13
2016
Q2
$8.69M Buy
260,242
+138
+0.1% +$4.4K 2.28% 10
2016
Q1
$7.31M Buy
260,104
+10,293
+4% +$294K 2% 20
2015
Q4
$7.65M Buy
249,811
+12,792
+5% +$402K 2.18% 14
2015
Q3
$7.06M Buy
237,019
+7,551
+3% +$242K 2.17% 13
2015
Q2
$7.3M Buy
229,468
+1,875
+0.8% +$61.1K 2.1% 12
2015
Q1
$7.51M Buy
227,593
+1,786
+0.8% +$56.8K 2.19% 6
2014
Q4
$6.67M Buy
225,807
+1,307
+0.6% +$37.5K 1.96% 11
2014
Q3
$6.3M Buy
224,500
+3,282
+1% +$92.1K 1.95% 11
2014
Q2
$6.23M Buy
221,218
+7,783
+4% +$222K 1.98% 8
2014
Q1
$6.5M Buy
213,435
+2,090
+1% +$62.3K 2.21% 4
2013
Q4
$6.14M Sell
211,345
-725
-0.3% -$21.1K 2.14% 6
2013
Q3
$5.78M Buy
212,070
+4,673
+2% +$127K 2.2% 4
2013
Q2
$5.51M Buy
+207,397
New +$5.73M 2.25% 4

Other funds holding PFE

Callahan Advisors's PFE Position: Q1 2026 in Review

Callahan Advisors reduced its Pfizer (PFE) stake by 10% in Q1 2026, selling an estimated $1.74M and leaving 562,533 shares worth $15.8M. The position accounts for 1.32% of the portfolio, ranked #27.

Callahan Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $23.4M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Callahan Advisors held 562,533 shares of Pfizer worth $15.8M as of Q1 2026.
  • Callahan Advisors sold 65,185 Pfizer shares in Q1 2026, an estimated $1.74M.
  • Pfizer made up 1.32% of Callahan Advisors's portfolio in Q1 2026, its #27 holding.
  • Callahan Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Callahan Advisors's Pfizer position peaked at $23.4M in Q4 2021.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.